Holistic strategies needed to diagnose and treat endometriosis
Endometriosis has been woefully under-recognized in the medical community, and consequently, the delay between onset and diagnosis is often quite long, with some women waiting up to 12 years for a diagnosis. Endometriosis affects about 10% of women, and about 190 million women worldwide live with endometriosis.

Holistic strategies needed to diagnose and treat endometriosis
Endometriosis has been woefully under-recognized in the medical community, and consequently, the delay between onset and diagnosis is often quite long, with some women waiting up to 12 years for a diagnosis. Endometriosis affects about 10% of women, and about 190 million women worldwide live with endometriosis.
ONC-206 shows potential to prevent colorectal cancer recurrences
Recurrence rates and acquired treatment resistance in colorectal cancer have been linked to colorectal cancer stem cells, which are a subpopulation of slowly dividing cells within the tumor environment.
Lilly to develop ALS therapeutics against targets identified under Verge collaboration
Eli Lilly & Co. has elected to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) from its collaboration with Verge Analytics Inc. (dba Verge Genomics).
EDG-7500 reverses nonobstructive hypertrophic cardiomyopathy in vivo
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disorder with around 85% of people with HCM remaining undiagnosed. There are no treatments approved for nonobstructive HCM (nHCM) to date.
DAN-222 demonstrates efficacy in pediatric solid tumor models
DAN-222 is a polymeric nanoparticle covalently conjugated with the topoisomerase I inhibitor camptothecin, which has previously demonstrated promising clinical activity in heavily pretreated patients with breast cancer (NCT05261269).
FAP inhibitor AZD-2389 improves liver fibrosis and MASH
Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with diet-induced MASH.
Aeovian Pharmaceuticals patents new CD38 inhibitors
Aeovian Pharmaceuticals Inc. has prepared tricyclic fused imidazole compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma and more.
Sangamo’s ST-503 receives IND clearance for idiopathic small fiber neuropathy
Sangamo Therapeutics Inc. has received IND clearance from the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN).

BioWorld Insider Podcast

In the newest BioWorld Insider podcast, Ranjit Bindra, founder of Modifi Biosciences Inc., talks about how his company got creative on the rocky road to a multibillion-dollar buyout.

Conferences

Synrx Therapeutics reports new PARG inhibitor
New compound
Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors with/without homologous recombination deﬁciency (HRD).
XPR1 unveiled as therapeutic target in lung cancer
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Tumor cell survival is dependent on phosphate homeostasis, which requires high amounts of energy. Researchers have demonstrated that the silencing of xenotropic and polytropic retrovirus receptor 1 (XPR1) led to reduced tumor growth in an ovarian cancer cell line xenograft, and similar...
MT-303 exerts antitumoral activity in liver cancer
Cancer
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making it an interesting target for therapy.
BB-201, a potent first-in-class anti-Her2/anti-Trop2 bispecific ADC candidate
Cancer
Researchers from Bright Biologics LLC presented the discovery and preclinical characterization of a novel bispecific anti-Her2/anti-Trop2 antibody-drug conjugate (ADC), BB-201.

More in Conferences

Cancer

NY-303 is first-in-class NK cell engager
Conferences
Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell surface receptor involved in NK cell activation and the elimination of target cancer cells.

Infection

Greek scientists patent new spike glycoprotein/ACE2 interaction inhibitors for SARS-CoV-2
Coronavirus
A group of researchers have disclosed spike glycoprotein (SARS-CoV-2; COVID-19 virus)/ACE2 interaction inhibitors in a new patent.

Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate
Regulatory
Arcturus Therapeutics Holdings Inc. has received IND clearance from the FDA to begin a phase I study of ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus.
Ifast raises $6.5M for technology to fight antimicrobial resistance
Financings
Ifast Diagnostics Ltd. raised $6.5 million (£5 million) in seed funding to bring its rapid Antimicrobial Susceptibility Testing (AST) platform to the market. The company’s technology is vital in the fight against antimicrobial resistance and the funds will be used to conduct clinical trials to get...

More in Infection

Neurology/psychiatric

GPR40 as a promising new target for Parkinson’s disease
Scientists at Gachon University and their collaborators investigated the neuroprotective effects of the GPR40 agonist TUG-469 in models of Parkinson’s disease (PD).
Despite women’s health inroads, lackluster funding impedes progress
Analysis and data insight
While women make up half the world’s population and own two out of every five businesses, there are substantial knowledge gaps about conditions affecting their health – mostly due to decades of research excluding women from clinical trials and investment decisions.
New α2B-adrenoceptor agonists disclosed in Alceptor patent
Patents
Alceptor Therapeutics Inc. has divulged α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
DDX17 involved in neurodevelopmental delay, research finds
Conferences
DEAD-box helicase 17 (DDX17) is an RNA helicase involved in the early phases of neuronal differentiation. Researchers have identified a total of 13 patients presenting with neurodevelopmental phenotypes and who harbored de novo monoallelic variants in the DDX17 gene. The phenotype was characterized...
Poseida Therapeutics offers preclinical highlights of CAR T pipeline
CAR T
Poseida Therapeutics Inc. has updated progress made in its early-stage pipeline of differentiated T stem cell memory cell-rich allogeneic CAR T therapies in oncology and autoimmune diseases.

More in Neurology/psychiatric

Endocrine/metabolic

Astrazeneca exercises option for type 1 diabetes Treg cell therapy program with Quell
License
Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to license the therapy for further development and commercialization, resulting in a milestone payment...

More in Endocrine/metabolic

Biomarkers

Novel KDM3B variant found in atypical Diets-Jongmans case
Conferences
The KDM3B gene encodes the histone lysine demethylase lysine-specific demethylase 3B, which is involved in the regulation of transcription.

VSX2 variant linked to retinal detachment risk
Conferences
Researchers from the U.K. have analyzed whole-genome sequencing data from 7,276 cases and 236,741 controls in the UK Biobank to perform gene-level and a variant-level exome-wide association study analysis to identify variants related to retinal detachment.
Machine learning links microbiome composition to bacterial load
Artificial intelligence
Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and inflammatory bowel disease. A study counting gut microbiome proposes that microbial load, rather than...

More in Biomarkers

Gastrointestinal

Evotec International divulges new LPAM-1 antagonists
Patents
Evotec International GmbH has synthesized integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.
Numab and Kaken Pharmaceutical sign agreement for ND-081 for inflammatory bowel disease
Antibody
Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have signed a new collaboration and option agreement to develop ND-081, a multispecific antibody for the treatment of inflammatory bowel disease.
Series B financing at Trex Bio supports immunology pipeline development
Financings
Trex Bio Inc. has closed an oversubscribed $84 million series B financing round to support development of its pipeline of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
China Hinye Pharmaceutical describes new H+/K+-ATPase inhibitors
Patents
China Hinye Pharmaceutical Co. Ltd. has identified pyrrole sulfonyl compounds and deuterated derivatives acting as H+/K+-ATPase inhibitors reported to be useful for the treatment of peptic ulcers, Zollinger-Ellison syndrome, gastroesophageal...
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease
Werewolf Therapeutics Inc. has expanded its pipeline with the addition of a novel IL-10 Indukine development candidate, WTX-921, for inflammatory bowel disease (IBD) and potentially other inflammatory diseases.
PROTAC shows promise in liver cancer models
Cancer
Liver diseases are responsible for around two million deaths every year. Among them, hepatocellular carcinoma (HCC), particularly at late stages, presents limited therapeutic options and a dismal survival rate.

More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple background Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.

Recent episodes:

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription